Europe approves first specific treatment for CLOVES syndrome

In June 2026, the European Medicines Agency (EMA) approved the use of alpelisib for the treatment of CLOVES syndrome, a rare genetic disorder that until recently had no targeted therapy available in Europe. The decision comes four years after the drug received approval from the U.S. Food and Drug Administration (FDA). CLOVES syndrome is a congenital condition caused by mutations in the PIK3CA gene, leading to abnormal and disproportionate overgrowth of body tissues, including limbs, fatty tissue and internal organs. The disorder can result in severe deformities, vascular malformations and chronic pain from birth. The name CLOVES is an acronym describing the syndrome’s main features: congenital abnormalities, lipomatous overgrowth, tissue overgrowth, vascular malformations, epidermal lesions and spinal or skeletal deformities. Symptoms vary widely among patients. While some experience mild asymmetry, others face significant physical deformities, mobility limitations, scoliosis, chronic pain, respiratory problems and complications linked to vascular abnormalities. Because of its rarity, diagnosis often requires genetic testing and assessment by a multidisciplinary medical team. Until recently, treatment focused mainly on managing symptoms through surgery and supportive care. Alpelisib is the first therapy to target the underlying biological mechanism of the disease. The drug inhibits the PI3K protein, which becomes overactive due to PIK3CA mutations, helping to slow abnormal tissue growth and reduce disease-related complications. Although alpelisib is not a cure and does not eliminate the genetic mutation, it represents a major advance in the management of CLOVES syndrome. Patients will still require ongoing medical monitoring, but the treatment offers new hope for improving quality of life and controlling disease progression. The EMA’s approval marks an important milestone for patients and families affected by this rare condition and highlights the growing role of precision medicine in treating genetic diseases.The post Europe approves first specific treatment for CLOVES syndrome first appeared on All PYRENEES.